464 related articles for article (PubMed ID: 31609479)
1. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
2. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
3. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
7. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
9. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
11. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
12. Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700).
Merlano MC; Denaro N; Vecchio S; Licitra L; Curcio P; Benasso M; Bagicalupo A; Numico G; Russi E; Corvo' R; Bruzzi P;
Oncology; 2020; 98(11):763-770. PubMed ID: 32629446
[TBL] [Abstract][Full Text] [Related]
13. Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
Xiang M; Colevas AD; Holsinger FC; Le QX; Beadle BM
J Natl Compr Canc Netw; 2019 Sep; 17(9):1065-1073. PubMed ID: 31487677
[TBL] [Abstract][Full Text] [Related]
14. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Adkins D; Ley J; Michel L; Wildes TM; Thorstad W; Gay HA; Daly M; Rich J; Paniello R; Uppaluri R; Jackson R; Trinkaus K; Nussenbaum B
Oral Oncol; 2016 Oct; 61():1-7. PubMed ID: 27688097
[TBL] [Abstract][Full Text] [Related]
15. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Haddad RI; Massarelli E; Lee JJ; Lin HY; Hutcheson K; Lewis J; Garden AS; Blumenschein GR; William WN; Pharaon RR; Tishler RB; Glisson BS; Pickering C; Gold KA; Johnson FM; Rabinowits G; Ginsberg LE; Williams MD; Myers J; Kies MS; Papadimitrakopoulou V
Ann Oncol; 2019 Mar; 30(3):471-477. PubMed ID: 30596812
[TBL] [Abstract][Full Text] [Related]
17. The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC.
Tasoulas J; Lenze NR; Farquhar D; P Schrank T; Shen C; Shazib MA; Singer B; Patel S; Grilley Olson JE; Hayes DN; Gulley ML; Chera BS; Hackman T; Olshan AF; Weiss J; Sheth S
Cancer Med; 2021 May; 10(10):3231-3239. PubMed ID: 33934525
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.
Riaz N; Sherman E; Koutcher L; Shapiro L; Katabi N; Zhang Z; Shi W; Fury M; Wong R; Wolden S; Rao S; Lee N
Am J Clin Oncol; 2016 Feb; 39(1):27-31. PubMed ID: 24401670
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
20. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
